BPMC250117P115000
- 30.70
- 0.000.00%
Blueprint Medicines Newsroom
IonQ, H&E Equipment Services And ImmunityBio Are Among Top Mid Cap Gainers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio?
Blueprint Prep Recognized Among Built In's 2025 Best Places to Work
Insider Sale: Director at $BPMC (BPMC) Sells 5,000 Shares
Mixed Prospects for Blueprint Medicines: Hold Rating Maintained Amid Promising Trials and Side Effect Concerns
JMP Securities Maintains Blueprint Medicines(BPMC.US) With Buy Rating, Maintains Target Price $125
Cautious Hold Rating for Third Harmonic Bio Amid Competitive Pressure From Blueprint Medicines
Blueprint Stock Soars 18% on Encouraging 2025 Growth Strategy
5 Biotech Stocks Worth Adding to Your Portfolio in 2025
A Quick Look at Today's Ratings for Blueprint Medicines(BPMC.US), With a Forecast Between $105 to $155
Express News | Blueprint Medicines Corp : Leerink Partners Raises Target Price to $98 From $89
Blueprint Medicines (BPMC) Stock Jumps 18.2%: Will It Continue to Soar?
Blueprint Medicines Shares Up 10% on $4B Revenue Projection for Mastocytosis
Blueprint Medicines Surges Over 10% as 2025 Growth Strategy Ignites Investor
Intra-Cellular Therapies, Standard BioTools, SI-BONE And Other Big Stocks Moving Higher On Monday
Express News | Blueprint Medicines Shares Are Trading Higher After the Company Reported a Year-over-year Increase in FY24 AYVAKIT Revenue Results
Wedbush Reiterates Outperform on Blueprint Medicines, Lowers Price Target to $124
A Quick Look at Today's Ratings for Blueprint Medicines(BPMC.US), With a Forecast Between $105 to $151
Blueprint Medicines (BPMC) Gets a Buy From TD Cowen
Express News | Blueprint Medicines Corp : Wedbush Cuts Target Price to $124 From $135
Express News | Needham Reiterates Buy on Blueprint Medicines, Maintains $135 Price Target